“…In a model of neuropathic pain, systemically (subcutaneously) applied loperamide reversed mechanical allodynia by activation of peripheral -receptors (Guan et al, 2008). Peripheral restriction was further pursued with arylacetamide morphinan-based [nalfurafine, [8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid (DiPOA)] and with peptidic compounds [Tyr-Arg-Phe-Lys-NH 2 (DALDA)] (for reviews, see Schü tz et al, 2003;DeHavenHudkins and Dolle, 2004;Chu et al, 2007). Some of these were subsequently abandoned, mostly because the chemical addition of hydrophilic residues led to reduced affinity at opioid receptors or because higher doses were able to penetrate the blood-brain barrier.…”